Warhound Secures $200 Million to Engineer the Future of Military K-9s

The U.S. military’s reliance on imported working dogs is about to meet a domestic rival.

Warhound, a startup emerging from stealth mode on Thursday, has raised $200 million in a funding round that values the company at $1.2 billion. The investment comes from a consortium of major players, including Sequoia, 8VC, and Corner Ventures, as well as In-Q-Tel, a venture firm supported by the CIA and other U.S. intelligence agencies.

The core problem the company aims to solve is a critical gap in the nation’s working dog supply. According to the launch announcement, more than 80% of the U.S. military’s current working dogs are sourced from Europe. Furthermore, fewer than half of these imported animals are deemed fit for service upon arrival. This dependency has created a dwindling domestic supply, leaving law enforcement and emergency response teams increasingly reliant on foreign nations for animals that play pivotal roles in national security.

To reverse this trend, Warhound is leveraging the biotechnology of Colossal Biosciences. The goal is to engineer dogs with specific characteristics suited to demanding missions, such as bomb detection and search operations. Ben Lamm of Colossal Biosciences, who met Anduril co-founder Palmer Luckey at a conference a year ago, identified that many current working dogs fail due to inherited health issues, including poor eyesight, cancer, hip dysplasia, and muscle atrophy. By studying top-performing breeds like the Belgian Malinois and German Shepherd, the team has created a biobank of cell lines to edit genes, aiming to enhance health, longevity, and sensory capabilities like olfactory precision.

Beyond genetics, the dogs will be equipped with hardware and software provided by Anduril. This technology is designed to improve situational awareness for both the dogs and their handlers. Lamm described the concept as adding protective gear with data sensors, such as bulletproof vests that transmit information back to operators. He emphasized that these enhancements are meant to operate "on top of the dog, not in the dog," ensuring that the animals are safer and more effective in the line of duty while also protecting their human partners.

The business structure involves Colossal owning equity in Warhound and licensing its technology, while Luckey serves as a partner without holding equity. Colossal, previously known for de-extinction projects like the dodo and mammoth, is applying its AI-driven gene cloning technology to this new venture. Viagen, another company owned by Colossal, will partner with Warhound to handle the cloning process, utilizing technology that boasts a high success rate and is already used in endangered species programs.

The first batch of these engineered dogs is scheduled to be cloned and incubated soon, with births expected early next year. The company aims to have the animals in service within two years. While pricing has not yet been determined, Warhound intends to sell to first responders, the Department of Defense, military service groups, and police forces. Lamm noted that the company has already briefed numerous government groups regarding the initiative and that each dog will undergo standard military working dog training before being managed by its purchaser.

To address concerns about animal welfare, Warhound is working under the guidance of the American Humane Society to certify its training programs. The American Humane Society stated in a comment that it is pleased to be involved, noting its commitment to science and ethics in ensuring the animals are treated humanely. Additionally, there is a hope that retired Warhound dogs will be integrated into the Society’s Military Working Dog Reunification Program, which provides homes for retired military animals.